Cancer patients potentially overlooked in COVID-19 vaccine rollout

Via Peters

Photo:Morsa Images/Getty Images Almost two-thirds of U.S. states failed to prioritize cancer patients for COVID-19 vaccinations despite recommendations from the Centers for Disease Control and Prevention, according to a study presented this week at the annual meeting of the Radiological Society of North America. Cancer patients are particularly vulnerable to the […]

Black women are more likely to develop lymphe

Via Peters

SAN ANTONIO – Black women experienced higher rates of breast cancer-related lymphedema than white women, and Black race was the strongest predictor of lymphedema development, according to results presented at the San Antonio Breast Cancer Symposium, held December 7-10, 2021.     Lymphedema is a well-known side effect of breast cancer […]

ctDNA Promising Biomarker in Ribociclib, Letrozole-Treated HR+/HER2- Advanced Breast Cancer

Via Peters

The presence of detectable mutation in a baseline liquid biopsy appeared to be a negative prognostic factor for women with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer treated with first-line ribociclib and letrozole, according to the results of the BioItaLEE trial (ClinicalTrials.gov Identifier: NCT03439046). The absence of a target mutation […]

Some Treatment Outcomes Do Not Differ Between Black and White Patients With Breast Cancer, But Disparities Persist

Via Peters

Patient race did not significantly impact the percentage of patients who had no detectable disease in biopsied/surgically removed tissue after treatment (known as pathologic complete response) or event-free survival in patients with high-risk breast cancer who received presurgical chemotherapy. However, disparities existed for a subgroup of women who did not […]

Trastuzumab ADC Active in HER2-Low, HER2-Undetected Breast Cancer

Via Peters

SAN ANTONIO — A headline-making antibody-drug conjugate (ADC) continued to impress breast cancer specialists by demonstrating activity in tumors with low HER2 expression and in some breast cancers with undetectable HER2. As expected, trastuzumab deruxtecan (T-DXd, Enhertu) showed robust activity in HER2-overexpressing metastatic breast cancer, producing objective responses in 71% […]

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

Via Peters

Summary Background Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate the relationship of RCB with long-term prognosis across different phenotypic subtypes of breast cancer, to assess generalisability in […]

Patient Race Doesn’t Significantly Impact Pathological CR After Neoadjuvant Therapy for Breast Cancer

Via Peters

Although significant disparities for a subgroup of women who did not achieve a pathologic complete response (pCR) were observed, patient race did not significantly impact pCR and event-free survival (EFS) in patients with high-risk breast cancer who received targeted neoadjuvant chemotherapy, according to results presented by Beverly Kyalwazi, BS, at […]